Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Kyowa Kirin notches second win

Posted 14 September 2021 AM

The second of two drugs that Kyowa Kirin aimed to bring onshore in setting up its Australian subsidiary has been green-lighted by the TGA, and the Japanese pharma says it isn't giving up on securing subsidised access for patients.

Crysvita, a human monoclonal antibody, has been approved under priority review for children (aged 1 and over) and adults with X-linked hypophosphatemia, marking the first biologic therapy for the rare and progressive condition in Australia.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Melb pharma registers first copy
Long list of generic versions of PBS-listed drugs